Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The huge bid flashing is telling us where this is going EZ.
I was just teasing it a little bit before.
ACLS looks like we're gonna have to wait for next week's fireworks.
ALCS. LeTs close strong.
Kind of seems like it doesnt it?
Yes, maybe towards the end of day we can challenge that.
mix in a few cialis as well. lets see what happens.
lol. nice.
Give it a few extra just to be sure. lol
ACLS nice and steady. Its ready to challenge that 1.48 later today I think.
Creeping up closer to that 1.48.
This 1.44 wall is gonna fall soon.
If not this week then next.
ACLS very quiet and slow day. No sellers. Waiting for ignition.
agree.
That ANX looks great for today. Havent been playing too much the last week or so. Just holding some big boards and accumulating.
Locked and loaded my friend.
Looking for ACLS to bounce hard here.
Indeed a beast
Good morning everyone
Agree.
Yes, they're trying to load. Will not be here for long.
PGCX NEWS AH!
PanGenex Signs Licensing Deal to the Enter the $600 Million Spirulla Market
To Develop Retail Products Using the All-Natural, Superfood Spirulla
Nov. 30, 2009 (Business Wire) -- PanGenex Corporation (Pink Sheets:PGCX), a global nutraceutical and dietary supplement manufacturer and marketer, announced today that it has solidified plans to expand its retail product line with the addition of spirulla. Spirulla, a blue green algae, is an abundant and sustainable natural source of protein, essential fatty acids, vitamins, B12 and minerals that has been used as a dietary health supplement for centuries. Through a licensing agreement with Greenr U Corp., PanGenex has access to a state-of-the-art algae growing system to begin producing its own high-quality spirulla. The Company plans to incorporate spirulla into select product lines as well as develop an array of new, heart-healthy nutraceutical and dietary supplements featuring spirulla.
“Spirulla is considered a 'superfood,' packed with 100% natural energy-boosting ingredients. We believe a move into the $600 million spirulla market is a major step toward sustaining long-term growth,” said John Stanton, Chairman of PanGenex. “Our goal is to reach sales of $2 million in our first year of production and increase exponentially as growing acreage is added and our additional products are brought to market.”
PanGenex plans to develop a variety of spirulla-infused heath products ideal for health-conscious consumers, aging baby-boomers, vegetarians and more. “We believe we can produce the highest quantity and purest form of spirulla available on the market today. Our algae will be grown in nutrient-enhanced fresh water within a closed loop vertical system, thus avoiding the contamination typical of outdoor ponds. We expect to deliver our first products from this production facility in early summer 2010. Our scientists and product consultants are researching strains for other specialized beneficial use that a dedicated facility will allow us to grow to our product specifications.”
PanGenex initially expects to grow approximately 40,000 gallons of oil or 10,000 lbs of spirulla powders per acre per year. Dry powder spirulla sells for in excess of $50 per lb, while other specialized strains sell for in excess of $400 per lb. Other uses for algal oils and powder include protein enhancement products as part of the $27 billion sports nutrition market and in oil capsules as a replacement for certain types of liquid fish oil capsules. PanGenex products will be marketed to health and whole food stores and through its various existing outlets.
About PanGenex Corporation
PanGenex pursues business opportunities in the $70 billion dollar nutraceutical and dietary supplement industry. With a focus on the cardiovascular health segment, PanGenex develops and markets sector-leading, patented or patent pending, condition-specific nutraceuticals and topical over-the-counter (OTC) drugs and personal care products. Many of its products contain the purest grade of nutraceutical components available anywhere without a prescription. Since 2006, PanGenex has voluntarily submitted its product labels for review by the FDA without incidence. PanGenex products are currently sold to healthcare practitioners in 20 U.S. states, Canada, Puerto Rico, Canada, Brazil and Australia, in fine retail establishments and on the Internet including: www.PanGenex.com, www.Calgenex.com and www.HeartHealthyWorld.com.
Disclaimer:
CAUTIONARY STATEMENT ABOUT FORWARD-LOOKING STATEMENTS
This press release contains "forward-looking statements," which are statements related to future, not past, events. In this context, the forward-looking statements often include statements regarding our goals, plans, projections and guidance regarding our financial position, results of operations, market position, pending and potential future acquisitions and business strategy, and often contain words such as "expects," "anticipates," "intends," "plans," "believes," "seeks" or "will." Any such forward-looking statements are not assurances of future performance and involve risks and uncertainties that may cause results to differ materially from those set forth in the statements. These risks and uncertainties include, among other things, (a) general economic and business conditions, (b) the level of strategic partner incentives, (c) the future regulatory environment, (d) our cost of financing, (e) our ability to complete acquisitions and dispositions and the risks associated therewith, and (f) our ability to retain key personnel. These factors, as well as additional factors, could affect our forward-looking statements. We urge you to carefully consider this information. We undertake no duty to update our forward-looking statements, including our earnings outlook. The statements in this press release have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.
Source: Business Wire (Nov 30, 2009 16:39:06 EST) News by QuoteMedia www.quotemedia.com
ACLS NEWS:
Axcelis Introduces the Optima HDx High Current Implanter
Nov. 30, 2009 (GlobeNewswire) --
BEVERLY, Mass., Nov. 30, 2009 (GLOBE NEWSWIRE) -- Axcelis Technologies, Inc. (Nasdaq:ACLS) today announced the introduction of the Optima HDx high dose implanter, which brings unprecedented beam current and performance levels to the high dose space. An extension of the company's Optima HD platform, the Optima HDx has been designed to provide chipmakers dramatically increased productivity and capital efficiency. The system is the latest tool in Axcelis' versatile Optima implant family, and is available now for shipment.
"In today's competitive environment, semiconductor manufacturers are simultaneously challenged with increasing fab productivity, reducing costs as well as meeting the requirements of next generation device manufacturing," said Bill Bintz, senior vice president of marketing. "The new Optima HDx was expressly designed to meet these challenges. We've worked closely with customers over the downturn and the results speak for themselves. The new Optima HDx provides customers the advanced process capabilities required for emerging new device architectures, while setting a new standard for high dose productivity."
The new Optima HDx features a unique combination of enhancements to maximize beam current, minimize beam set up time and eradicate energy contamination to deliver the most precise and repeatable performance in the high dose space. The system's unique spot beam technology and short beamline deliver the industry's highest drift beam currents up to 36mA, or 38%, higher than its competitors. To further enhance performance, its patented AutoTune beam tuning system has significantly accelerated both tune times and success rates, providing up to a 60% advantage over competitive systems, for increased fab productivity. Key to the systems enabling technology is the proprietary RadiusScan, which ensures the best across-wafer dose and angle process uniformity, as well as repeatability.
Learn more about the Optima HDx and Axcelis' other ion implant and cleaning products at the upcoming SEMICON Japan, on December 2-4th, at the Makuhari Messe in Chiba, Japan. Visit booth #2B-401.
About Axcelis
Axcelis Technologies, Inc. (Nasdaq:ACLS), headquartered in Beverly, Massachusetts, provides innovative, high-productivity solutions for the semiconductor industry. Axcelis is dedicated to developing enabling process applications through the design, manufacture and complete life support of ion implantation and cleaning systems. The company's Internet address is: www.axcelis.com.
CONTACT: Axcelis Technologies, Inc.
Editorial/media:
Maureen Hart
978.787.4266
Maureen.hart@axcelis.com
Financial community:
Stephen Bassett
978.787.4110
Stephen.bassett@axcelis.com
Source: GlobeNewswire (Nov 30, 2009 08:32:46 EST) News by QuoteMedia www.quotemedia.com
Added YMI off 50 MA. Great long term play.
its a difficult fill. sometimes one needs to sit on the ask for 10 15 minutes .
nothing. price taken down on small bid whacks. nothing to worry about.
It is chart. I remember those days. I hope our YMI follows CENX.
It usually takes a week or two at least to complete such process.
are you pretty optimistic that this deal will happen?
EZ, you think ACLS is still good here?
Try typing in eworld.com in your browser and interestingly enough apple website opens.
Just a matter of time now. Great pick up. Wish I had more. Good luck to us.
ACLS bid building up
It is an excellent entry I agree.
ACLS want to see a nice strong 0.80 cent break. The weekly chart looks marvelous.
Dont know, theyre probably hiding their size
We need your help!!! :)
ACLS big wall at 80 cents
She's itching to go EZ! Been around 80 cent area all morning.